See an interview with an RV247 Ebola
vaccine trial volunteer.
Not exact matches
Researchers at Oregon Health & Science University are currently looking for
volunteers that can be tested during an upcoming clinical
trial for a
vaccine that may cure HIV, the virus that causes AIDS.
In households where women between the ages of 15 and 40 were pregnant,
volunteer participants were administered either influenza
vaccine or placebo as part of a randomized, placebo - controlled Phase 4 clinical
trial.
By some estimates one in 5,000 Zika patients develops GBS, but the question of whether the
vaccine — which would contain some viral DNA if not the whole virus — will also cause this rare side effect will not be adequately answered in small
trials that contain less than 100
volunteers.
In the
trials, a total of 67 healthy adult
volunteers received two injections, four weeks apart: 55 received the ZPIV
vaccine and 12 received a placebo.
An experimental
vaccine to prevent the mosquito - borne viral illness chikungunya elicited neutralizing antibodies in all 25 adult
volunteers who participated in a recent early - stage clinical
trial conducted by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Tested in a U.S. - sponsored
trial that involved more than 16,000
volunteers in Thailand, the
vaccine was administered in six injected doses starting in 2006 to half of the group, and the other half received a placebo.
The reliably high percentage of those who develop viremia following exposure to this challenge virus is another advantage — when most or all
volunteers develop viremia or other signs of infection, clinical
trials can enroll relatively small numbers of people but still achieve answers to such questions as whether a candidate
vaccine protects against infection, she noted.
A clinical
trial in which
volunteers were infected with dengue virus six months after receiving either an experimental dengue
vaccine developed by scientists from the National Institutes of Health (NIH) or a placebo injection yielded starkly contrasting results.
Just a few weeks ago, WHO said that using any of the experimental drugs or
vaccines in the pipeline simply wasn't in the cards, because none of them have been through a phase I clinical study, the type of
trial in which medical products are tested on healthy
volunteers to study their toxicity.
In the
trial of the bivalent
vaccine,
volunteers received one of two doses.
A new clinical
trial in which the
vaccine will be given intravenously to 51
volunteers is scheduled to start next month at VCR; another
trial in Tanzania is on the drawing board.
Further
trials are planned for Switzerland, Mali, and Uganda; Ballou says altogether about 150
volunteers will receive the single - dose
vaccine.
Druilhe says planned
trials of the MSP3
vaccine with adult
volunteers in Burkina Faso have been delayed by red tape and slow funding, but he hopes to begin them sometime next year.
This can eliminate, or at least greatly reduce, long and costly
trials, and fewer
volunteer subjects will be exposed to potentially dangerous
vaccines.
Human challenge
trials like this one are an extremely efficient way for scientists to tell whether a particular
vaccine is effective, but they are rarely conducted because of the ethical dilemma of the risk it places on
volunteers who are purposely exposed to a virus.
If monkeys are protected by the
vaccine, and there are no signs of adverse effects, then human
volunteer trials can not be far away.»
The Step study, an international HIV
vaccine trial co-sponsored by the National Institute of Allergy and Infectious Diseases and the pharmaceutical company Merck, was halted in 2007 when the
vaccine failed to prevent HIV infection in
volunteers or affect the virus load in those infected.
MHRP's molecular epidemiologists played a key role on a research team that analyzed the HIV - 1 genome sequences from infected
volunteers in the Step HIV
vaccine trial.
It is also acknowledges the vital contributions of approximately 20,000
volunteers enrolled in AIDS
vaccine trials around the world today who have selflessly committed to advancing research.
The U.S. Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR) initiated a Phase 2 clinical
trial to evaluate the safety and immunogenicity of a prime - boost Ebola
vaccine regimen in both healthy and HIV - infected
volunteers.
We are in the midst of an unprecedented time in HIV
vaccine research; we have four concurrent efficacy
trials underway, which will collectively enroll 12,200
volunteers in the search for an HIV
vaccine over the next few years.
If the methadone liquid got people off injecting heroin, the
volunteers» risk of infection would slump and they would be of little use to the
vaccine trial.
Saint Louis University researchers announced plans last month to recruit
volunteers for a
vaccine trial.
Glenda Gray, executive director of the Wits Health Consortium's perinatal HIV research unit in South Africa, presented data today at the HIV R4P conference in Cape Town indicating that the prime - boost
vaccine candidates initially tested in the RV144
trial in Thailand — the only HIV
vaccine trial to date to show any efficacy — induced cross-clade immune responses in a Phase I safety
trial conducted in South Africa, with immunogenicity similar to or greater than that of the responses induced in Thai
volunteers.
At the International AIDS Society conference in Paris, scientists announced that in an early - stage clinical
trial, a new HIV
vaccine regimen generated antibody responses in 100 percent of
volunteers in most arms of the study.
At least 80 healthy
volunteers aged 18 to 35 are to receive doses of the
vaccine on differing schedules as part of a phase 1 clinical
trial, the agency said.